Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO].

Abstract:

:The Japanese encephalitis vaccine IC-51 (IXIARO) is an inactivated virus (strain SA(14)-14-2) that is manufactured in cultured Vero cells and is currently being developed for preventive vaccination against the Japanese encephalitis virus. black triangle Administration of IXIARO as a two-dose treatment in healthy adults provided high levels of seroprotection against Japanese encephalitis virus. Immune responses at 56 days post-vaccination, including seroconversion rates and geometric mean titres, were noninferior to those seen with a currently available licensed vaccine. Seroprotection was achieved 1 week after second vaccination. black triangle Long-term seroprotection was also observed with the vaccine, with seroconversion rates and geometric mean titres maintained at both 6 and 12 months post-vaccination. black triangle Coadministration with a hepatitis A vaccine had no effect on the immunogenicity of IXIARO. Additionally, the vaccine immunogenicity was not compromised in subjects with pre-existing vaccine-induced antibodies for tick-borne encephalitis, a related flavivirus. black triangle Vaccine immunogenicity was also observed in paediatric volunteers, with seroconversion rates not significantly different to an active comparator at 56 days post-vaccination. black triangle The safety and tolerability profile of IXIARO was generally similar to that of placebo with respect to systemic adverse events, and was associated with a numerically lower frequency of local injection site adverse events than the active comparator vaccine. [fig: see text]

journal_name

Drugs

journal_title

Drugs

authors

Duggan ST,Plosker GL

doi

10.2165/00003495-200969010-00008

subject

Has Abstract

pub_date

2009-01-01 00:00:00

pages

115-22

issue

1

eissn

0012-6667

issn

1179-1950

pii

8

journal_volume

69

pub_type

杂志文章

相关文献

DRUGS文献大全
  • Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.

    abstract:BACKGROUND:Generic drugs are approved on the basis of pharmaceutical equivalence and bioequivalence. Some drug products have unique structural or functional attributes, necessitating modified approaches to bioequivalence determinations. OBJECTIVE:The aim of this systematic review was to identify studies that evaluated...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0382-1

    authors: Kesselheim AS,Polinski JM,Fulchino LA,Isaman DL,Gagne JJ

    更新日期:2015-04-01 00:00:00

  • Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

    abstract::Gatifloxacin (Tequin) is an 8-methoxy fluoroquinolone approved in the US for use in the treatment of community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), acute sinusitis, uncomplicated and complicated urinary tract infections (UTIs), pyelonephritis, gonorrhoea and uncomplicated skin an...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565050-00007

    authors: Keam SJ,Croom KF,Keating GM

    更新日期:2005-01-01 00:00:00

  • Continuous-use ethinylestradiol/levonorgestrel 20microg/90microg: as an oral contraceptive.

    abstract::The continuous-use combination oral contraceptive ethinylestradiol/levonorgestrel 20microg/90microg suppresses gonadotropins, and subsequently ovulation and endometrial thickening, and suppresses breakthrough bleeding. Amenorrhoea and absence of breakthrough bleeding increase in incidence with extended administration....

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767160-00010

    authors: Wagstaff AJ

    更新日期:2007-01-01 00:00:00

  • The role of beta-blockers in the treatment of cardiomyopathy and ischaemic heart failure.

    abstract::As first reported by our group in 1975, severe heart failure due to idiopathic dilated cardiomyopathy could be improved in patients receiving beta-blocker therapy starting at a very low dose and followed by a stepwise increase. Since then, these results have been confirmed by our own group and by others, and similar r...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199400474-00006

    authors: Hjalmarson A,Waagstein F

    更新日期:1994-01-01 00:00:00

  • The Multifactor Primary Prevention Trial in Göteborg, Sweden. Comparison with a previously untreated population sample.

    abstract::All male inhabitants of the city of Göteborg, who were born between 1915-1922 and 1924-1925 were included in the trial, and were 47 to 55 years of age on entry to the study in 1970 to 1973. One-third of these men were randomly allocated to an intervention group, whilst the other two-thirds acted as controls. Men of al...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198600311-00009

    authors: Wilhelmsen L,Berglund G,Elmfeldt D,Samuelsson O,Svardsudd K

    更新日期:1986-01-01 00:00:00

  • Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.

    abstract::Sitagliptin (Januvia(®), Xelevia™, Glactiv(®), Tesavel(®)) is an orally administered, potent and highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4) and was the first agent of its class to be approved for use in the management of adults with type 2 diabetes. Numerous randomized placebo- or active comparator-c...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0169-1

    authors: Plosker GL

    更新日期:2014-02-01 00:00:00

  • The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

    abstract::The endothelin family of peptides are extremely potent endogenous vasoconstrictor and pressor agents. Of the 3 isoforms, endothelin-1 is the major isoform produced by the vascular endothelium and is, therefore, likely to be of most importance for regulation of vascular function. Two endothelin receptor subtypes have s...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199651010-00003

    authors: Ferro CJ,Webb DJ

    更新日期:1996-01-01 00:00:00

  • Antibiotics in neonatal infections: a review.

    abstract::The bacteria most commonly responsible for early-onset (materno-fetal) infections in neonates are group B streptococci, enterococci, Enterobacteriaceae and Listeria monocytogenes. Coagulase-negative staphylococci, particularly Staphylococcus epidermidis, are the main pathogens in late-onset (nosocomial) infections, es...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958030-00003

    authors: Fanos V,Dall'Agnola A

    更新日期:1999-09-01 00:00:00

  • Drug treatment of tropical parasitic infections: recent achievements and developments.

    abstract::Drug development offers potential solutions to a number of tropical health diseases, although the expense of pharmaceutical research and lack of return on investment has limited the production of new agents. The greatest successes have been through the development of single dose therapy and mass treatment control prog...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060050-00002

    authors: Stephenson I,Wiselka M

    更新日期:2000-11-01 00:00:00

  • Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis.

    abstract::Alemtuzumab (Lemtrada®) is an anti-CD52 monoclonal antibody approved in the EU for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS). In phase 3 trials in patients with active RRMS, intravenous alemtuzumab was more effective than subcutaneous interferon β-1a in terms of decreasing relapse ra...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01437-2

    authors: Syed YY

    更新日期:2021-01-01 00:00:00

  • Oral etoposide in lymphoma.

    abstract::Etoposide is one of the most active agents for the therapy of lymphomas. Oral etoposide has proven to be active in and clearly beneficial for patients with previously treated lymphomas. The optimal dose and schedule of oral etoposide for use in combination chemotherapy are still uncertain, but low daily doses (50 to 1...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958003-00006

    authors: Greco FA

    更新日期:1999-01-01 00:00:00

  • Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.

    abstract::Isradipine, a dihydropyridine derivative, inhibits the inward calcium flux through 'slow' channels of cardiac and vascular tissue, thereby eliciting potent coronary, cerebral and peripheral vasodilatation. In comparison with other calcium channel blockers the drug offers the advantages of minimal cardiodepressant acti...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199040010-00004

    authors: Fitton A,Benfield P

    更新日期:1990-07-01 00:00:00

  • Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder.

    abstract::Aripiprazole (Abilify®) is an atypical antipsychotic indicated for the treatment of mania associated with bipolar I disorder. It is unique in its class, as it is a partial agonist of dopamine D(2) and D(3), and serotonin 5-HT(1A) receptors and a modest antagonist of 5-HT(2A) receptors. This article reviews the pharmac...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11208320-000000000-00000

    authors: Dhillon S

    更新日期:2012-01-01 00:00:00

  • Remission, a therapeutic goal in inflammatory arthropathies? Clinical data from adalimumab studies.

    abstract::In recent years, there have been major advances in the management of rheumatoid arthritis (RA), leading to the development of tumour necrosis factor (TNF) antagonists. With these agents, it is possible to arrest joint damage and, by treating early in the disease course, to prevent joint damage. It is also now thought ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666140-00001

    authors: Montecucco C

    更新日期:2006-01-01 00:00:00

  • Retention in care and medication adherence: current challenges to antiretroviral therapy success.

    abstract::Health behaviors such as retention in HIV medical care and adherence to antiretroviral therapy (ART) pose major challenges to reducing new HIV infections, addressing health disparities, and improving health outcomes. Andersen's Behavioral Model of Health Service Use provides a conceptual framework for understanding ho...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-015-0373-2

    authors: Holtzman CW,Brady KA,Yehia BR

    更新日期:2015-04-01 00:00:00

  • Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function.

    abstract::Because of inappropriate signals from the volume-regulation system and a reduction in renal blood flow, the kidney is not able to prevent sodium and water retention in chronic congestive heart failure (CHF). A brief summary of normal renal function and renal involvement in CHF is given and a study of renal function in...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-199000394-00004

    authors: Ljungman S,Laragh JH,Cody RJ

    更新日期:1990-01-01 00:00:00

  • Endothelial function. General considerations.

    abstract::The endothelium is involved in both the physiological regulation of vascular tone and the structural transformation of the vessel under pathological conditions. Under physiological conditions, endothelial cells continuously secrete nitric oxide (NO), which relaxes smooth muscle cells and ensures vessel patency. Damage...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199700531-00003

    authors: Haller H

    更新日期:1997-01-01 00:00:00

  • White coat hypertension and related phenomena. A clinical approach.

    abstract::In this paper, several clinical problems associated with the diagnosis of hypertension are discussed. Blood pressure variability and reactivity are factors underlying the difficulties in the diagnosis of hypertension. These phenomena are interrelated and mixed. White coat hypertension (WCH), referring to the phenomeno...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199300462-00017

    authors: Ocón-Pujadas J,Mora-Maciá J

    更新日期:1993-01-01 00:00:00

  • The management of epilepsy in the 1990s. Acquisitions, uncertainties and priorities for future research.

    abstract::The pharmacological treatment of epilepsy has made considerable progress during the last decade, due to improved knowledge of the clinical pharmacology of individual drugs, acquisition of new information on the factors affecting response and need for drug treatment, and development of promising new agents. Once a clin...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549050-00004

    authors: Beghi E,Perucca E

    更新日期:1995-05-01 00:00:00

  • Systematic review and guide to selection of selective serotonin reuptake inhibitors.

    abstract::A meta-analysis of 20 short term comparative studies of 5 selective serotonin reuptake inhibitors (SSRIs; citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline) has shown no difference in efficacy between individual compounds but a slower onset of action of fluoxetine. There were suggestions that fluoxetine c...

    journal_title:Drugs

    pub_type: 杂志文章,meta分析

    doi:10.2165/00003495-199957040-00005

    authors: Edwards JG,Anderson I

    更新日期:1999-04-01 00:00:00

  • Brodalumab: First Global Approval.

    abstract::Brodalumab (Lumicef(®)) is a human monoclonal immunoglobulin G antibody that is being developed by Kyowa Hakko Kirin in Japan, where it has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Brodalumab binds with high affinity to interleukin (IL)-...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-016-0634-8

    authors: Greig SL

    更新日期:2016-09-01 00:00:00

  • Statins and menopause.

    abstract::During the reproductive period, women generally have lower low-density lipoprotein (LDL) cholesterol and higher high-density lipoprotein cholesterol than age- and diet-matched men. However, these possibly antiatherogenic characteristics of lipoproteins are changed to a potentially atherogenic profile after menopause. ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262170-00002

    authors: Moghadasian MH

    更新日期:2002-01-01 00:00:00

  • Practical treatment guide for dose individualisation in cancer chemotherapy.

    abstract::Dosages of anticancer drugs are usually calculated on the basis of a uniform standard, the body surface area (BSA). Although many physiological functions are proportionate to BSA, overall drug clearance is only partially related to this parameter. Consequently, following administration of equivalent drug dosages based...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856060-00006

    authors: Canal P,Chatelut E,Guichard S

    更新日期:1998-12-01 00:00:00

  • Appropriate use of antitussives and protussives. A practical review.

    abstract::As a symptom of an underlying condition, cough is one of the most common reasons patients see physicians. To the majority, a cough means that 'something is wrong' and it causes exhaustion and/or self-consciousness. Patients find these reasons as well as effects on lifestyle, fear of cancer and/or AIDS or tuberculosis ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199346010-00006

    authors: Irwin RS,Curley FJ,Bennett FM

    更新日期:1993-07-01 00:00:00

  • Azelnidipine.

    abstract::Azelnidipine is a new dihydropyridine calcium channel antagonist with selectivity for L-type calcium channels that has recently been approved in Japan for the treatment of patients with hypertension. Results from clinical trials showed that, in 95 patients with mild-to-moderate hypertension, long-term treatment with a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363230-00004

    authors: Wellington K,Scott LJ

    更新日期:2003-01-01 00:00:00

  • Inhibiting costimulatory activation of T cells : a viable treatment option for rheumatoid arthritis?

    abstract::There is now good evidence that T cells play a central role in the inflammatory pathway that leads to the persistent synovitis that causes joint damage in rheumatoid arthritis (RA). T cells require two signals to become activated. The second step in the activation of T cells involves costimulatory pathways, the best d...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767010-00001

    authors: Pollard LC

    更新日期:2007-01-01 00:00:00

  • Rabeprazole: a review of its use in acid-related gastrointestinal disorders.

    abstract::Rabeprazole is an inhibitor of the gastric proton pump. It causes dose-dependent inhibition of acid secretion and has a more rapid onset of action than omeprazole. Duodenal ulcers healed faster after treatment with rabeprazole 20 or 40 mg/day than placebo or ranitidine 150 mg 4 times daily and at a generally similar r...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958040-00014

    authors: Langtry HD,Markham A

    更新日期:1999-10-01 00:00:00

  • Managing cancer-related anorexia/cachexia.

    abstract::Cancer-related anorexia/cachexia (CAC) is a complex phenomenon in which metabolic abnormalities, proinflammatory cytokines produced by the host immune system, circulating tumour-derived catabolic factors, decreased food intake, and probably additional unknown factors, all play different roles. This review examines the...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161040-00004

    authors: Mantovani G,Macciò A,Massa E,Madeddu C

    更新日期:2001-01-01 00:00:00

  • Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

    abstract::Alfuzosin, a new quinazoline derivative, acts as a selective and competitive antagonist of alpha 1-adrenoceptor-mediated contraction of prostatic, prostatic capsule, bladder base and proximal urethral smooth muscle, thereby reducing the tone of these structures. Consequently, urethral pressure and resistance, bladder ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199345030-00008

    authors: Wilde MI,Fitton A,McTavish D

    更新日期:1993-03-01 00:00:00

  • Tipranavir: a ritonavir-boosted protease inhibitor.

    abstract::Tipranavir is a non-peptidic HIV-1 protease inhibitor. It binds strongly and selectively, has a favourable resistance profile, and is administered orally twice daily with a subtherapeutic dosage of ritonavir in a 'boosted' regimen (TPV/r) in order to increase its bioavailability. Analysis of clinical isolates from tre...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565120-00005

    authors: Croom KF,Keam SJ

    更新日期:2005-01-01 00:00:00